Array BioPharma (ARRY)
Array BioPharma Revenue Growth: 7.13%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ARRY Revenue Growth Rankings
| Overall | 51st percentile | 2107 of 4358 |
| Sector | 43rd percentile | 256 of 456 in Healthcare |
| Industry | 43rd percentile | 71 of 126 in Biotechnology |
ARRY Revenue Growth Range, Past 5 Years
| Minimum | -40.20% | Sep 2007 |
| Maximum | 226.3% | Jun 2010 |
| Average | 30.87% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these ARRY related companies
ARRY News
$AMRN Marine 889 patent prosecution update http://stks.co/3tFJ $ARRY $GALE $VTUS $PFE $KERX
about 9 days ago by imhobutdydd
about 9 days ago by imhobutdydd
$FFN http://stks.co/3sxu $FFN $GALE $PSOF $ARRY Full blog post and video here http://stks.co/3sxv
about 10 days ago by LincolnList
about 10 days ago by LincolnList
$AMRN Marine 889 patent prosecution update http://stks.co/3soe $ARRY $GALE $VTUS $PFE $KERX
about 10 days ago by imhobutdydd
about 10 days ago by imhobutdydd
Movers: $FFN #FriendFinder1.52+37 $KONG KongZhong6.56+64 $ARRY ArrayBioPh3.74+09YH $ZNGA #Zynga8.21 $MEG MediaGen4.16+1 http://stks.co/3siH
about 10 days ago by InvestorsGuru
about 10 days ago by InvestorsGuru
Notable 52-Week Highs and Lows of the Day 05/17: (ARRY) (NTES) (PCYC) High; (WFR) (VALE) (CLWR) Low
May 17, 3:42PM Street Insider
May 17, 3:42PM Street Insider
Array BioPharma, RCM Technologies, Other Stocks Hit 52-Week Highs Thursday
May 17, 12:31PM Fox Business
May 17, 12:31PM Fox Business
$ARRY Mentioned more than normal on StockTwits - Currently at 8 x average daily social activity
about 10 days ago by TradeIdeasQuant
about 10 days ago by TradeIdeasQuant
$ARRY is -5.5% down since open on unusual high volume but still 2.7% up since close.
about 10 days ago by TradeBot
about 10 days ago by TradeBot
RT @justfurkids ASCO12 "Most significant cancer drug data came from $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgp
about 11 days ago by russe9
about 11 days ago by russe9
ASCO12 "Most significant cancer drug data came from phase III studies by $AVEO $EXEL & phase II studies by $ARRY " http://stks.co/3rgj
about 11 days ago by justfurkids
about 11 days ago by justfurkids
Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting
May 16, 4:00PM Business Wire
May 16, 4:00PM Business Wire
RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech
about 11 days ago by WolfsBiotechs
about 11 days ago by WolfsBiotechs
Array BioPharma and Genentech's Strategic Alliance Voted Breakthrough Alliance of 2012
May 14, 6:30PM Business Wire
May 14, 6:30PM Business Wire
Listen to $ARRY Q3 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3bA4
about 26 days ago by earningscast
about 26 days ago by earningscast
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012
Apr 30, 4:00PM Business Wire
Apr 30, 4:00PM Business Wire
http://stks.co/3aI7 Earnings after hours: $ADVS $ARRY $APC $FST, $JEC, $KAMN, $VECO, $SFLY
about 27 days ago by freefdawatchlistcom
about 27 days ago by freefdawatchlistcom
Array BioPharma Names Liam Ratcliffe, M.D., Ph.D., to Board of Directors
Apr 30, 8:00AM Business Wire
Apr 30, 8:00AM Business Wire
Array BioPharma to Report Financial Results for the Third Quarter of Fiscal 2012 on April 30, 2012
Apr 23, 4:01PM Business Wire
Apr 23, 4:01PM Business Wire
Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
Apr 16, 8:30AM Business Wire
Apr 16, 8:30AM Business Wire
Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer
Apr 04, 9:29AM Business Wire
Apr 04, 9:29AM Business Wire
Array BioPharma to Present at the Cowen and Company 32nd Annual Health Care Conference
Feb 27, 1:00PM Business Wire
Feb 27, 1:00PM Business Wire
Piper Jaffray Maintains Array Biopharma at Neutral, Lowers PT from $4 to $3.5
Feb 15, 9:02AM Benzinga
Feb 15, 9:02AM Benzinga
Array BioPharma Announces Closing of Public Offering of Common Stock and Exercise of Overallotment Option
Feb 14, 9:57AM Business Wire
Feb 14, 9:57AM Business Wire
Array BioPharma to Present at the Leerink Swann Global Healthcare Conference
Feb 09, 5:30PM Business Wire
Feb 09, 5:30PM Business Wire
Array BioPharma (ARRY) Prices 20 Milllion Share Offering at $2.60/Share
Feb 09, 9:04AM Street Insider
Feb 09, 9:04AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ARRY | 3.46 | -0.19 | -5.21% | 282.16M |
| ARRS | 12.32 | -0.01 | -0.08% | 1.418B |
| ARR | 6.95 | +0.05 | +0.72% | 984.88M |
| ARQL | 5.87 | +0.05 | +0.86% | 316.69M |
| AROW | 23.85 | -0.05 | -0.21% | 283.82M |
| ARO | 19.19 | +0.17 | +0.89% | 1.554B |
| ARNA | 6.00 | -0.04 | -0.66% | 1.083B |
| ARMH | 23.23 | +0.13 | +0.56% | 10.46B |
| ARLP | 58.99 | +0.17 | +0.29% | 2.176B |
| ARL | 2.69 | +0.00 | +0.00% | 30.99M |
